RxDoctor Payments Data

Heather Sarkis, PA

Medical · Coeur D Alene, IDNPI 1023118122

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.

$2,761in general payments, 2019–2025

Across 158 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$487
  • Johnson & Johnson$365
  • AstraZeneca$198
  • Pfizer$186
  • Lilly USA, LLC$177
  • Amgen$162
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,761 in reported general payments places this provider in the 85th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$28,885
Medicare patients
148
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$35,307
MounjaroTirzepatide13$17,653
XareltoRivaroxaban16$16,479
Breo ElliptaFluticasone/Vilanterol13$5,075
PremarinEstrogens, Conjugated11$2,189
Levothyroxine Sodium181$1,237
Gabapentin88$1,225
Potassium Chloride51$1,175
Duloxetine Hcl39$1,121
Albuterol Sulfate HfaAlbuterol Sulfate42$1,082
Metoprolol Succinate41$886
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$859
Rosuvastatin Calcium50$795
Pregabalin12$683
Ezetimibe18$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$186$37,49655 claims
Lilly USA, LLCMounjaro$177$17,65313 claims
Johnson & JohnsonXarelto$365$16,47916 claims
GSKBreo Ellipta$102$5,07513 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$39$23911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 medical providers in Idaho.

Other medical in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →